This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
If you hadn’t already noticed, the clinical research enterprise has well and truly entered the era of “bigdata,” artificial intelligence (AI), and machine learning. Edited by Gary Cramer The post Recognizing the Real People Behind the BigData and Artificial Intelligence in Clinical Research appeared first on ACRP.
The webinar will also cover: How the necessary routine and research data can be collected in registries in a further processable form by patients and healthcare professionals. Optimising and exploiting data for use in rare disease-specific research and studies. About the panel.
And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar. Navigating rare disease research and treatment.
The rise of bigdata analytics, artificial intelligence, and machine learning has revolutionized drug discovery, development, and marketing. With advancements in genomics and biotechnology, there is a move towards tailoring treatments to individual patients based on their genetic makeup.
By leveraging data from genomic studies and electronic health records, marketers can identify niche markets and craft messages that speak directly to the needs and concerns of specific patient populations. One major area of regulatory change is the emphasis on patient data protection.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content